CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering

T cells engineered to express a chimeric antigen receptor (CAR) have re-shaped the way hematological malignancies are treated. Despite the overwhelming early clinical success, CAR-T therapies are associated with severe side-effects, disease relapse and often exhibit limited efficacy. In this Review...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology advances 2019-11, Vol.37 (7), p.107411-107411, Article 107411
Main Authors: Panagopoulou, Theano I., Rafiq, Qasim A.
Format: Article
Language:English
Subjects:
Antigens
Biotechnology
Chimeric antigen receptor
Clinical outcomes
Disease control
Immunotherapy
Lymphocytes
Molecular structure
Neoplasms
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T cells engineered to express a chimeric antigen receptor (CAR) have re-shaped the way hematological malignancies are treated. Despite the overwhelming early clinical success, CAR-T therapies are associated with severe side-effects, disease relapse and often exhibit limited efficacy. In this Review article we summarize the most recent biotechnological advances that have been developed to enhance the efficacy and specificity of CAR-T therapies, as well as to address the key challenges associated with them. We place particular emphasis on the most recent clinical data that indicate which CAR-T populations are the most relevant to clinical success, and indicate how the molecular structure of the CAR receptor can affect clinical outcome. Finally, we outline what we believe is the next generation of immunotherapies.
ISSN:0734-9750
1873-1899
DOI:10.1016/j.biotechadv.2019.06.010